Tollys

TOLLYS, founded in 2015 in France, is carving a niche in the immuno-oncology landscape with its groundbreaking work on specific TLR3 agonists. Emerging from leading European cancer research hubs, TOLLYS is addressing a significant gap by focusing on homogeneous TLR3 agonists critical for inducing tumor cell death and enhancing immunogenic responses. The company’s proprietary candidate, TL-532, patented in 2018, showcases promising preclinical results, notably its efficacy in anti-tumor responses and recurrence prevention, as well as its synergy with immune checkpoint inhibitors.

Targeting Non Muscle Invasive Bladder Cancer (NMIBC) unresponsive to BCG treatment, TL-532 aims to satisfy an unmet medical need, with clinical trials slated to commence in 2021. With its potential for expedited market entry and broad applicability across various cancers, TOLLYS presents a compelling case for investment. A recent €2.30M Series A funding round, underpinned by Investisseurs privés, underscores investor confidence in the venture’s innovative approach and robust market potential.